Sapient Capital LLC Sells 24,770 Shares of Pfizer Inc. $PFE

Sapient Capital LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 5.5% during the 2nd quarter, Holdings Channel reports. The firm owned 427,068 shares of the biopharmaceutical company’s stock after selling 24,770 shares during the period. Sapient Capital LLC’s holdings in Pfizer were worth $10,284,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in PFE. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the 4th quarter worth about $26,000. HFM Investment Advisors LLC increased its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the last quarter. Evolution Wealth Management Inc. raised its position in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Abound Financial LLC purchased a new position in Pfizer in the fourth quarter valued at about $31,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer during the 2nd quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Better-than-expected Q2 results supported the stock. Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate and revenue of $15.03 billion versus expectations of $14.40 billion. The company also raised its 2026 revenue outlook, helping offset concerns about declining COVID-related sales. Pfizer Inc. Q2 2026 Earnings Call Summary
• Positive Sentiment: Pipeline progress is improving Pfizer’s longer-term outlook. Analysts highlighted the company’s broader pipeline, including the potential obesity treatment berobenatide and PF-07328948. Berobenatide is being compared with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, although Pfizer still faces significant development and competitive hurdles. Pfizer’s Next Weight-Loss Weapon
• Positive Sentiment: Pfizer and BioNTech advanced COVID-19 vaccine studies. A new Phase 4 study of a variant-adapted booster, along with progress on a next-generation pediatric booster, could support future vaccine demand and preserve the partnership’s commercial position. Variant-Adapted COVID-19 Booster Study
• Neutral Sentiment: Analyst opinion remains mixed. Some analysts are bullish after the earnings beat and pipeline updates, while RBC Capital maintained a Hold rating, indicating that valuation and execution risks continue to limit conviction. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: Patent expirations and obesity-program uncertainty remain overhangs. Investors are questioning whether Pfizer’s pipeline can replace revenue lost to upcoming patent cliffs, while previous obesity setbacks make the berobenatide opportunity particularly important but far from assured. Pfizer’s Patent and Pipeline Outlook
• Negative Sentiment: COVID product sales remain weak. Pfizer’s COVID pill revenue reportedly fell 95%, underscoring the company’s continuing dependence on non-COVID products and pipeline launches to drive growth. Pfizer COVID Pill Revenue Decline

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.70 on Monday. The company’s fifty day moving average price is $25.02 and its 200-day moving average price is $26.17. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market capitalization of $152.20 billion, a price-to-earnings ratio of 35.14 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Pfizer in a research note on Monday, August 3rd. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. Finally, Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.